Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Noteable

T.ONC

RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

- Clear path forward on key elements of the planned potential registration...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

" .. now well-positioned ..."  not only in breast cancer...

June 27, 2024

T.ONC

RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

As ONCY stated in today's press release .. " We are now well...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Should read: " Today's news over the FDA's rejecting...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Today's news oer the FDA rejecting Daiichi Sankyo's Merck & Co. -...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:It Was Just A Typo

The registered agent is responsible for receiving all official documents...

June 27, 2024

T.ONC

RE:RE:Big pharma is set to keep signing bigger deals in 2024

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc...

June 27, 2024

T.ONC

RE:RE:It Was Just A Typo

That said ... a retraction wouldn't be necessary if ONCY intends to...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:It Was Just A Typo

It appears the US agent simply filed using a boiler plate template containing...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:It Was Just A Typo

Not exactly -- the primary responsibility the agent is to act on behalf...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:It Was Just A Typo

Again I ask ... if it was such a big concern to you "Why didn't you...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:It Was Just A Typo

This registration statement on Form S-8 by Oncolytics Biotech Inc. (the...

June 27, 2024

T.ONC

RE:RE:RE:RE:It Was Just A Typo

Why didn't you simply contact the agent of service for clarificatrion? ...

June 27, 2024

T.ONC

RE:RE:RE:It Was Just A Typo

So then we ask ... what was the reason for filing a POA.

June 27, 2024

T.ONC

RE:RE:It Was Just A Typo

Should read: " ... if ONCY intends to be acquired sometime very...

June 27, 2024

T.ONC

RE:It Was Just A Typo

Unlikely a typo and an odd response by Tim McCarthy, if it was he who...

June 27, 2024

T.ONC

RE:Big pharma is set to keep signing bigger deals in 2024

June 27, 2024 - Biogen appears to be subtly signaling it has a larger...

June 27, 2024

T.ONC

RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

June 27, 2024 -  FDA has rejected Daiichi Sankyo’s Merck & Co...

June 27, 2024

T.ONC

RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Wayne Pisano, Interim CEO and Chair of the Board of Oncolytics, commented...

June 27, 2024

T.ONC

RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Repost - Further to the potential of ONCY's pelareorep in combination...

June 27, 2024

Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next

Featured Company

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc. V.VSR

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ... view more »